Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Biovitrum AB acquires the pharmaceutical company Arexis AB
Mandate

Biovitrum AB acquires the pharmaceutical company Arexis AB

October 03, 2005

Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.

Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026

Vinge has advised Resurs in connection with its strategic partnership with Kustom

 Vinge has advised Resurs in connection with its strategic partnership with Kustom (formerly Klarna Checkout), a fast-growing player in the digital commerce sector. The partnership enables Resurs to accelerate its strategic development by offering a check-out solution to its merchants, built on Kustom’s market-leading infrastructure.
March 25, 2026